First sound pharmaceutical stroke new drugs must first enter the ® health insurance directory

In recent years, with the increasing attention of China's pharmaceutical industry to independent innovation, coupled with the adjustment of medical insurance policy, more and more patients can more timely enjoy the fruits of innovative drugs, bringing survival benefits.
2020, China's vast number of ischemic stroke patients have also ushered in a new hope.
July 30, Synthesic Pharmaceuticals Class 1 innovative drug First New ® (Idarafeng rightol injection with a thick solution) was approved for sale by the NMPA, the only innovative drug approved for sale in the global stroke treatment field in the last five years, which can significantly reduce acute ischemic stroke (AIS) caused brain nerve damage, and extend the existing treatment window from 24 hours to 48 hours.
December 28th, the results of the 2020 health care negotiations came out, first the new ® was formally included in the health insurance directory, after entering the health insurance, the first must be the new ® treatment price of about 300 yuan, drug access will be greatly improved.
, according to the latest news, the new version of the medical insurance drug catalog will be officially implemented on March 1, 2021.
there is no doubt that drug access can not be separated from the "drug" and "price" support.
this new version of the health care catalog adjustment, the National Health Insurance Administration will be 2020 new market innovative drugs into consideration, can be seen through health insurance to benefit more patients determination.
new health insurance will be ® more patients when it goes on sale at the end of July and goes into health care at the end of December.
significantly improve the prognostication of patients 2 times the treatment time window China's stroke incidence rate is the highest in the world.
, according to the Global Burden of Disease Study, the age-standardized incidence of stroke in China has increased by 5.4% in 20 years, with 5.5 million new patients expected each year.
China Stroke Prevention and Control Report released in 2019, the number of stroke patients living with the disease in China has reached 13 million, resulting in a domestic stroke drug market of more than 100 billion.
, ischemic stroke, commonly known as "brain infarction", is the most important type of stroke in China.
However, the large and urgent clinical needs corresponding to the perennian barren drug use status quo, due to the complexity of the mechanism of brain nerve damage, the field for many years new drug research and development difficulties, in recent years, few new drugs approved, into an "embarrassing silence."
In July this year, the launch of the first must-have new ® (Idarafeng rightol injection with a thick solution) broke this long-term "embarrassing silence" situation - in terms of drug efficacy, the first new ® is an innovative neuro-protective agent, after 12 years of research and development It was finally proved that with a 4:1 ratio combination of Wydarafeng and rightol, it was possible to remove free fundamentals, anti-inflammatory and improve the blood-brain barrier and other multiple mechanisms of action, and the Phase III clinical study showed that it could significantly reduce and improve the brain nerve damage caused by acute ischemic stroke and improve the functional outcomes of patients.
In terms of treatment time, in a phase III study involving 1200 patients with acute ischemic stroke, phase III of randomized, double-blind, positive control and head-to-head comparison, the Idalafeng rightol injection showed clear therapeutic advantages over the one-way Italafon injection. Clinical safety is similar, greatly extending the existing treatment window from 24 hours to 48 hours, for the patient's life to win more golden treatment time, and more than 90% of ischemic stroke patients in China can not receive thrombosis and thrombosis treatment in an effective time, so the first new ® is of great significance for clinical treatment.
Based on the good results of phase® III clinical trials, professor Wang Congjun, an authoritative expert on neurological diseases and president of Tiantan Hospital in Beijing, said: "In the first half of 2021, China's clinical guidelines will be updated, and the first phase ® is expected to be included in the IIA-level recommendations."
" according to the introduction, the first must be new® from 2007 to date, over a period of 13 years, won 8 invention patents, the core patents in many countries and regions (the United States, Japan, Australia, Canada, Europe, Hong Kong, etc.) were authorized;
new signal: reducing the burden on patients encourages enterprises to innovate China has become the country with the highest lifetime risk of stroke and the highest burden of disease.
the socio-economic burden of stroke on China has reached 100 billion yuan per year, and the cost of direct treatment for the disease is about 50 billion yuan, not including indirect economic losses caused by the loss of the patient's labor force due to death or disability.
under such a heavy burden, it is imperative to seek treatment to improve the prognostic outcome of stroke patients and reduce the direct and indirect economic losses of stroke.
, the role of health care is also crucial.
past ten years, the per capita medical expenses of stroke patients in China have been increasing, and the per capita hospitalization costs of ischemic stroke patients have reached 9387 yuan.
at the same time, rural areas with poor economic conditions and poor payment level are the worst affected areas of stroke in China, and the incidence, prevalence and mortality rate of cerebrovascular diseases in rural areas are higher than among urban residents.
After the first new medical insurance, on the one hand, it can effectively improve the patient's nerve function, reduce disability, reduce the patient's hospitalization expenses, as well as the subsequent care, self-care capacity loss of the burden;
It is worth mentioning that in order to better meet the demand for newly listed drugs, the National Health Insurance Administration put drugs listed before August 17 this year into the scope of adjustment, reflecting the direction of support for new drugs, so this July's listing of the first new ® can enter the 2020 national health care negotiations.
it is worth noting that the prices of most varieties that have been successful in this year's health care negotiations have greatly reduced the medical burden on patients, while also taking into account the value of innovative research and development by enterprises, and further releasing the incentive direction of national policies for innovative drugs.
Can be seen that in recent years, auxiliary drug catalog, volume procurement, DRGs/DIP, basic medical insurance drug management interim measures, innovative drug negotiations and other related measures of health insurance control fees have landed, the overall thinking of medical insurance charges is also more clear, that is: strengthen the "health insurance strategic value-oriented purchase" of the long-term trend, strongly support "to meet unsotrolled clinical needs, significantly reduce the burden of patients, improve the clinical benefits of patients" varieties.
policy is not only a boon for patients, but also a strong needle for corporate innovation strategy.
new drug ® be approved for the market and rapid access to health insurance, access to a significant increase in the hope that the drug will benefit more stroke patients.
。